ECM
SUPN icon

Element Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Element Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-61,534
Closed -$2.82M – 990
2018
Q1 		$2.82M Buy
+61,534
New +$2.57M 0.07% 139

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Element Capital Management's SUPN Position: Q2 2018 in Review

Element Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2018, closing a stake of 61,534 shares — an estimated $2.82M sold.

Element Capital Management first reported a position in SUPN in Q1 2018 and held it in 1 quarter. The position peaked at $2.82M in Q1 2018. 320 funds tracked by Wall St. Rank hold SUPN as of Q2 2018.

  • Element Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Element Capital Management sold 61,534 Supernus Pharmaceuticals shares in Q2 2018, an estimated $2.82M.
  • Element Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Element Capital Management's Supernus Pharmaceuticals position peaked at $2.82M in Q1 2018.
  • 320 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.